We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

47 hedge funds and large institutions have $17.9M invested in Clearside Biomedical in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.16% less ownership

Funds ownership: 1.39% → 1.23% (-0.16%)

8% less funds holding

Funds holding: 51 → 47 (-4)

20% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 15

25% less capital invested

Capital invested by funds: $23.8M → $17.9M (-$5.86M)

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Holders
47
Holders Change
-4
Holders Change %
-7.84%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
12
Reduced
15
Closed
9
Calls
$80K
Puts
–
Net Calls
+$80K
Net Calls Change
-$24K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$450K
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$365K
3
BlackRock
BlackRock
New York
+$51.4K
4
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$47.7K
5
Renaissance Technologies
Renaissance Technologies
New York
+$46.2K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$2.34M
2
JJ
Johnson & Johnson
New Jersey
-$260K
3
CP
Castleview Partners
Texas
-$248K
4
Millennium Management
Millennium Management
New York
-$211K
5
Jane Street
Jane Street
New York
-$191K
Name Holding Trade Value Shares
Change 		Change in
Stake
CRC
26
Curi RMB Capital
Illinois
$32.5K – – –
Squarepoint
27
Squarepoint
New York
$27K +$26.8K +1,386 New
Charles Schwab
28
Charles Schwab
California
$26.3K – – –
IAIM
29
International Assets Investment Management
Florida
$26K -$20.6K -1,067 -44%
Mariner
30
Mariner
Kansas
$24.6K – – –
TSS
31
Two Sigma Securities
New York
$24.4K -$4.13K -214 -15%
TRCT
32
Tower Research Capital (TRC)
New York
$20.7K +$10.3K +534 +102%
SWA
33
Stratos Wealth Advisors
Ohio
$18.2K – – –
Cambridge Investment Research Advisors
34
Cambridge Investment Research Advisors
Iowa
$14K -$638 -33 -5%
JP Morgan Chase
35
JP Morgan Chase
New York
$13.5K -$213 -11 -2%
Commonwealth Equity Services
36
Commonwealth Equity Services
Massachusetts
$13K +$12.9K +667 New
RWM
37
Rockwood Wealth Management
Pennsylvania
$13K +$12.9K +667 New
Simplex Trading
38
Simplex Trading
Illinois
$8K +$1.68K +87 +25%
Bank of America
39
Bank of America
North Carolina
$7.92K +$560 +29 +8%
PNC Financial Services Group
40
PNC Financial Services Group
Pennsylvania
$7.26K – – –
Osaic Holdings
41
Osaic Holdings
Arizona
$1.56K -$773 -40 -33%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$1.42K – – –
CIBC Private Wealth Group
43
CIBC Private Wealth Group
Georgia
$1.38K – – –
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$1K +$734 +38 New
Russell Investments Group
45
Russell Investments Group
United Kingdom
$316 +$309 +16 New
CFD
46
Creative Financial Designs
Indiana
$130 – – –
Wells Fargo
47
Wells Fargo
California
$65 -$657 -34 -92%
Qube Research & Technologies (QRT)
48
Qube Research & Technologies (QRT)
United Kingdom
$5 -$6.96K -360 Closed
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$3 – – –
JJ
50
Johnson & Johnson
New Jersey
– -$260K -11,309 Closed
1
2
3

CLSD Hedge Fund Activity: Q2 2024 in Review

47 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2024, worth a combined $17.9M — down 25% from $23.8M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CLSD and 6 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 12 added.

The largest buyer was Vanguard Group, adding an estimated $450K. The largest seller was Armistice Capital, cutting an estimated $2.34M.

  • 47 institutional investors held Clearside Biomedical (CLSD) as of Q2 2024, down from 51 in Q1 2024.
  • Funds reported $17.9M of Clearside Biomedical stock for Q2 2024, down 25% quarter-over-quarter.
  • 6 funds opened new Clearside Biomedical positions in Q2 2024 and 9 closed out, a net change of -3 holders.
  • The largest Clearside Biomedical buyer in Q2 2024 was Vanguard Group, an estimated $450K added.
  • The largest Clearside Biomedical seller in Q2 2024 was Armistice Capital, an estimated $2.34M sold.

Based on aggregated 13F filings for Q2 2024.